IMRN NASDAQ Week ended 07 Aug 2026

Weekly Investor Report

Immuron Ltd ADR · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 1.03 USD
-5.4% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 6.5% above the Trend Line and sits at 20.7% of its 52-week range. The latest completed week returned -5.4%, after a -16.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 14d.

Setup score 22 out of 100
Latest Close 1.03 USD 7 Aug 2026
1W Return -5.4% latest completed week
4W Return -16.2% short-term follow-through
12W Return 2.6% quarterly tape
Trend Breadth 26.9% 14 of 52 weeks active
Volume Ratio 0.1x vs 13-week average
What is working
  • The trend backdrop is active with a 7-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 43.69% based on similar historical setup states.
  • The share remains more than 20% below its 52-week high.
  • The latest week was a sharp negative move.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -5.4% Latest completed week; four-week move -16.2%. Indicator stack 39/54 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 43.69% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 52/100 26 relevant articles in the latest sentiment read. Event risk 14d Next report is scheduled for 27 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 6.5% above the Trend Line and sits at 20.7% of its 52-week range. The latest completed week returned -5.4%, after a -16.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.1x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5212-week average 0.35

12-week confirmation

Trend active7/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.52Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -16.2% over four weeks, 2.6% over 12 weeks, and -39.7% over one year. The current trend has remained active for 7 consecutive weeks.

Performance by holding period

1W-5.4%
4W-16.2%
12W2.6%
26W27.9%
52W-39.7%
Active trend streak7 weeks
Active weeks in one year14
Trend breadth26.9%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.45Latest activity-pressure read.
Pressure change-47.2%Four-week change in activity pressure.
Leadership-28.83Latest relative-leadership reading.
RS change-45.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Dec 2025 Field coverage 85% Model confidence 68%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength59/100Blend of value, momentum, and quality. Underlying universe rank 42; rank 1 is best.
Value54/100Relative valuation strength. Underlying universe rank 47; rank 1 is best.
Quality51/100Profitability and accounting quality. Underlying universe rank 50; rank 1 is best.
Momentum53/100Medium-term price momentum. Underlying universe rank 48; rank 1 is best.
Growth54/100Revenue and earnings growth. Underlying universe rank 47; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
0.6x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-115.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
64.6%
Gross profit retained from each unit of revenue.
Operating margin
-69.5%
Operating profit retained from revenue.
Free-cash-flow margin
-73.9%
Free cash flow generated from revenue.
Return on invested capital
-212.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
59.5%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.0%
Cash dividends relative to market value.
Buyback yield
-4.8%
Net share repurchases relative to market value.
Shareholder yield
-4.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 26 relevant articles.

9 positive · 14 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings14dNext report is scheduled for 27 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-56.9%Distance below the 52-week high.
13-week volatility15.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher9 of 2616 weeks finished lower.
Best week+45.0%Week of 29 May.
Worst week-13.8%Week of 5 Jun.
Latest week-5.4%Week of 7 Aug.

Shape of recent returns

Strong gains7
Modest gains2
Flat weeks1
Modest losses6
Sharp losses10
Recent vol15.5%13-week weekly-return volatility.
Base vol12.0%52-week weekly-return volatility.
Up/down split20/31Count of positive and negative weeks in the 52-week window.
Average skew10.8% / -7.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape26/100

Trend, activity pressure, participation, and risk combine to a 26/100 tape read.

 Indicator analysis53/100

Latest 12-week confirmation: trend 7/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.52; No reversal markers Next-Week ExpectancyNegative 43.69%

Next-week expectancy is negative with a 43.69% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors53/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 82 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment52/100

Weighted news tone is neutral across 26 relevant articles.

Vir Biotechnology (NASDAQ:VIR) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS Insiders50/100

No recent insider transaction evidence is stored.

 Earnings14d

Next report is scheduled for 27 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 20261.03 USD-5.4%0.97 USD1.79 USD0.45-28.8384.3KOn
31 Jul 20261.09 USD-1.8%0.96 USD1.80 USD0.66-22.09108.4KOn
24 Jul 20261.11 USD-8.3%0.95 USD1.80 USD0.76-21.27192.8KOn
17 Jul 20261.21 USD-1.6%0.94 USD1.81 USD0.87-16.66113.5KOn
10 Jul 20261.23 USD11.8%0.94 USD1.82 USD0.86-19.78613.0KOn
3 Jul 20261.10 USD0.0%0.93 USD1.82 USD0.87-27.91111.1KOn
26 Jun 20261.10 USD3.8%0.94 USD1.83 USD0.95-28.36233.9KOn
19 Jun 20261.06 USD-10.9%0.96 USD1.83 USD1.02-35.12117.7KOff
12 Jun 20261.19 USD-4.8%0.98 USD1.84 USD1.06-26.55227.2KOff
5 Jun 20261.25 USD-13.8%1.00 USD1.84 USD1.05-22.16612.5KOff
29 May 20261.45 USD45.0%1.01 USD1.85 USD0.89-14.8112.3MOff
22 May 20261.00 USD-0.5%1.02 USD1.85 USD0.69-40.28127.7KOff
15 May 20261.00 USD24.9%1.06 USD1.86 USD0.57-40.39437.9KOff
8 May 20260.80 USD1.6%1.10 USD1.86 USD0.51-53.1369.6KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context